Ann: Cellmid's Evolis Successfully Launched in USA stores, page-16

Post hoc ergo propter hoc! The bonus timing was disgraceful and a kick in the guts to long suffering shareholders.

The opportunities out there for this management simply cannot be turned into any real outcomes; the long track record of mediocre outcomes and record low sp evidence this.

With due respect Pfarma, if anything is achieved by this errant management in the future it is not rational to say that a tacky, preemptive benefaction to the CEO today would be justified by it or that the recent legitimate protest against it would be a storm in a tea cup. The CEO’s cup is runneth over and we are left to thirst even more.

Question whether the loyalist views of regular posters here come what may (including shareholder wealth destruction) are acquiescental, camouflaged blind faith, naked blind faith, a rallying cry for support for the incumbent management, having a lend of us or all of the above crafted to suit the occasion.

The absence of activism is only achieving a cosy very slow speed ahead but time waits for no man.

Even a little dissent from the disciples here could just make a difference to the future of this sleeping giant as the compliant Board, over which the CEO holds sway, is in need of a wake up call for its wider responsibilities and accountability to shareholders.